The latest research & treatment news about Hepatitis C infection, diagnosis, symptoms and treatment.

Previous

3 Hep C Treatment Side Effects Aided by Probiotics

Back to News Homepage

Next

A New Combination of Hepatitis C Drugs Leading to High Remission Rates

NS5a Replication Complex Inhibitor Will Be Used in Future Studies

October 11, 2013

Print this page

A combination of NS5a and Simeprevir will be used in the treatment of chronic Hepatitis C in patients with compensated liver disease. These trials will prove helpful in future developments.

Medivir: Janssen Has Acquired an NS5a Replication Complex Inhibitor That Will Be Evaluated with Simeprevir in Future Clinical Development

STOCKHOLM, Sweden–(BUSINESS WIRE)–October 08, 2013–

Regulatory News:

Medivir AB (OMX: MVIR) announced that Janssen Pharmaceuticals, Inc. (Janssen) has acquired the investigational compound GSK2336805 (GSK805), an NS5a replication complex inhibitor in phase II development for the treatment of chronic hepatitis C. Janssen has acquired all rights to develop and commercialize GSK2336805 including in combination with other drugs. Janssen acquired the compound from an affiliate of GlaxoSmithKline plc, financial details of the agreement have not been disclosed.

Janssen plans to initiate phase II studies to evaluate the use of GSK805 in interferon-free combinations with simeprevir (TMC435) and TMC647055, Janssen’s non-nucleoside polymerase inhibitor, for the treatment of chronic hepatitis C in adult patients with compensated liver disease.

Continue reading this entire article:
http://online.wsj.com/article/PR-CO-20131008-906189.html

No Comments - be the first!
Share
Share

Previous

3 Hep C Treatment Side Effects Aided by Probiotics

Back to News Homepage

Next

A New Combination of Hepatitis C Drugs Leading to High Remission Rates

Requirements for using and reposting articles

Comments

HepatitisCentral.com provides information regarding hepatitis and liver disease. Comments are available to the community in order to discuss these topics and obtain answers to questions through community members. The Editors at HepatitisCentral.com will not be responding to questions or comments posed in article comments.